Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study. J of Skin 2023, 7 (2), s153. https://doi.org/10.25251/skin.7.supp.153.